The Federal Trade Commission (FTC) has entered into a conduct consent decree to put an end to its opposition to the Amgen-Horizon pharmaceutical merger, as announced on September 1, 2023. This move has gone against the antitrust enforcement agencies’ long-standing repugnance towards resolving competition matters in proposed mergers via consensual arrangements that limit certain behaviors. The norm, instead, has often been to stop the merger outright or address competition problems through divestitures.
JD Supra reports the antitrust enforcement agencies’ indicated opposition to consent decrees that halt certain conduct, as seen over the years, making this FTC-endorsed decree a notable change to said approach. This announcement came in on the Friday preceding Labor Day, increasing its significance in the legal world.
Traditionally, consent decrees have been perceived as less effective tools to curb competition issues arising from proposed mergers. This stems from the inherent challenges in monitoring compliance and the possibility of unforeseen competition issues cropping up post-merger. More often, the solution has been either nipping the proposed merger in the bud or ensuring competition concerns are quelled through divestitures.
However, in the unique case of the Amgen-Horizon merger, the FTC has opted to lean into a conduct consent decree to lay its challenges to rest. This exceptional move elicits curiosity among legal professionals worldwide, sparking discussions on the potential implications this case might have for upcoming high-stakes merger negotiations.